These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17619552)

  • 1. The unusual suspects: a surprise regarding reactions to omalizumab.
    Lieberman P
    Allergy Asthma Proc; 2007; 28(3):259-61. PubMed ID: 17619552
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.
    Price KS; Hamilton RG
    Allergy Asthma Proc; 2007; 28(3):313-9. PubMed ID: 17619560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience.
    Harrison RG; MacRae M; Karsh J; Santucci S; Yang WH
    Ann Allergy Asthma Immunol; 2015 Jul; 115(1):77-8. PubMed ID: 25963450
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylaxis to Mepolizumab and Omalizumab in a Single Patient: Is Polysorbate the Culprit?
    Bergmann KC; Maurer M; Church MK; Zuberbier T
    J Investig Allergol Clin Immunol; 2020 Aug; 30(4):285-287. PubMed ID: 32723701
    [No Abstract]   [Full Text] [Related]  

  • 5. How to manage hypersensitivity reactions to biological agents?
    Barbaud A; Granel F; Waton J; Poreaux C
    Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen.
    Varghese M; Lieberman P
    Allergy Asthma Proc; 2007; 28(3):320-3. PubMed ID: 17619561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an anaphylactoid reaction to omalizumab.
    Dreyfus DH; Randolph CC
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):624-7. PubMed ID: 16680936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization.
    Labella M; Castells M
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):623-629. PubMed ID: 33781937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.
    Cox L; Lieberman P; Wallace D; Simons FE; Finegold I; Platts-Mills T; Schwartz L
    J Allergy Clin Immunol; 2011 Jul; 128(1):210-2. PubMed ID: 21531014
    [No Abstract]   [Full Text] [Related]  

  • 11. Infusion reactions associated with monoclonal antibodies in patients with solid tumors. Introduction.
    Cmelak AJ; Goldberg RM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):5-6. PubMed ID: 19385160
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab: anaphylactic shock: sometimes occurs more than one hour after the injection.
    Prescrire Int; 2008 Feb; 17(93):22. PubMed ID: 18386396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors.
    Chung CH; O'Neil BH
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):14-7. PubMed ID: 19385162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
    Ertaş R; Özyurt K; Yıldız S; Ulaş Y; Turasan A; Avcı A
    Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):82-6. PubMed ID: 26996116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.
    Lin RY; Rodriguez-Baez G; Bhargave GA
    Ann Allergy Asthma Immunol; 2009 Nov; 103(5):442-5. PubMed ID: 19927545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab in asthma: approval and postapproval experience.
    Chiang DT; Clark J; Casale TB
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):3-16. PubMed ID: 16222080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaphylaxis to thymoglobulin: a case report and literature review.
    Kandil E; Alabbas H; Distant D
    J La State Med Soc; 2009; 161(5):279-81. PubMed ID: 19927941
    [No Abstract]   [Full Text] [Related]  

  • 18. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate.
    Perino E; Freymond N; Devouassoux G; Nicolas JF; Berard F
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):664-666. PubMed ID: 29481891
    [No Abstract]   [Full Text] [Related]  

  • 19. Treating atopic asthma with the anti-IgE monoclonal antibody.
    D'Amato G
    Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaphylaxis: implications of monoclonal antibody use in oncology.
    Gleich GJ; Leiferman KM
    Oncology (Williston Park); 2009 Feb; 23(2 Suppl 1):7-13. PubMed ID: 19385161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.